INEQUALITY OF FORMULARY COVERAGE OF COLORECTAL CANCER DRUGS AMONG TAIWAN'S NATIONAL HEALTH INSURANCE HOSPITALS
Author(s)
Huang WF1, Hsieh CF1, Cheng CW2, Cheng SH21Institute of Health & Welfare Policy, National Yang-Ming University, Taipei, Taiwan, 2Institute of Health Policy & Management, National Taiwan University, Taipei, Taiwan
Presentation Documents
OBJECTIVES: To examine: 1) formulary coverage for colorectal cancer drugs by different hospitals in Taiwan’s National Health Insurance(NHI); 2) how coverage varies by hospital level (medical center vs. regional hospital) and location; and 3) how coverage varies by drug characterist. METHODS: Nationwide cross-sectional survey of regional hospitals and medical centers in Taiwan during June to August, 2009. A validated and structured questionnaire was used as the research instrument. The outcome variables were formulary coverage, cost sharing tier, and utilization management tools (prior authorization, quantity limit, step therapy) for the drugs covered by insurance benefit or self-payment. We examined whether there was an association between hospital type (level, ownership and location) and drug characteristics (drug, costs, and years since approval) with these outcomes. RESULTS: A total of 95 hospitals having oncology department constituted the study group, with respond rate of 90.5% (86/95). For eight colorectal cancer drugs, the coverage rate ranged from 98.8% to 74.4% (leucovorin 95.3%; fluorouracil 98.8%; oxaliplatin 95.3%; irinotecan 88.4%; tegafur-uracil 95.3%; capecitabine 87.2%; cetuximab 74.4%; bevacizumab 79.1%). Capecitabine, cetuximab and bevacizumab are all original brand drugs; on the contrary, fluorouracil and tegafur-uracil are all generic sources. Cetuximab and bevacizumab have a lower proportion of being regularly prepared (68.8% and 76.5%, respectively), comparing to other six drugs with higher proportion than 85%. Besides the NHI reimbursement guidance, the proportion of having an in-hospital mandated rule was higher for cetuximab and bevacizumab (21.9% and 23.9%, respectively). Regardless of differences in hospital level, ownership or locations, the two most important factors influencing the decision making of formulary listing was the safety and effectiveness of the drug. CONCLUSIONS: Comparing to target therapy drugs, cetuximab and bevacizumab, patients had less accessibility barriers to traditional colorectal cancer drugs. Furthermore, the geographic differences have an impact on accessibility of such drugs by patients.
Conference/Value in Health Info
2010-05, ISPOR 2010, Atlanta, GA, USA
Value in Health, Vol. 13, No. 3 (May 2010)
Code
PCN126
Topic
Health Policy & Regulatory
Topic Subcategory
Health Disparities & Equity
Disease
Oncology